AbbVie Drug Reduces Skin-Disease Lesions in Late-Stage Trial
AbbVie said its experimental drug lutikizumab significantly reduced inflammatory lumps and abscesses in patients with a chronic skin disease, meeting the main goal of a late-stage study.
AbbVie (NYSE: ABBV) said Thursday that its experimental drug significantly reduced inflammatory lumps and abscesses in patients with a chronic skin disease, meeting the primary goal of a late-stage study. The company is counting on lutikizumab to expand its immunology franchise, and…